Sentinel Lymph Node Based Management or Routine Axillary Clearance? Three-year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial
- 485 Downloads
To determine whether the benefits of sentinel node based management (SNBM) over routine axillary clearance (RAC) at 1 year persisted to 3 years of follow-up.
A total of 1,088 women with clinically node-negative breast cancer were randomly assigned to the SNBM or RAC group. Upper limb volume, symptoms, and function were assessed at 1, 6, 12, 24, and 36 months after surgery objectively with upper limb measurements by clinicians and subjectively by patients’ using validated self-rating scales.
Upper limb volume increased in both groups over the first 2 years and differed between the two groups all time points beyond 1 month (P < 0.02) but then plateaued. Upper limb swelling was no worse in women who had axillary clearance as a two-stage procedure than in women assigned RAC as a one-stage procedure. Upper limb volume had increased 15 % or more in 6.0 % at 6 months and 17.6 % at 3 years in those assigned RAC versus 4.2 and 11.9 % in those assigned SNBM. Reductions in upper limb movement were also greater, with RAC than SNBM over 6 months, but improved and were similar in the two groups from 1 to 3 years. Subjective ratings of upper limb swelling, symptoms, dysfunction, and disability over 3 years were worse in the RAC group. Upper limb swelling at 3 years was rated severe by few women (1.1 %) but was rated as moderate by 9.4 % in the RAC group and 2.5 % in the SNBM group (P < 0.001).
The benefits of SNBM over RAC persist 3 years after surgery.
- 3.Smith MJ, Gill PG, Wetzig N, et al; Royal Australasian College of Surgeons SNAC Trial Group. Comparing patients’ and clinicians’ assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Res Treat. 2009;117:99–109.PubMedCrossRefGoogle Scholar
- 6.Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: national surgical adjuvant breast and bowel project phase III protocol B-32. J Clin Oncol. 2010;28:3929–36.PubMedCentralPubMedCrossRefGoogle Scholar
- 8.Krag D, Anderson SJ, Julian TB, et all. Sentinel lymph node resection compared with conventional axillary lymph node dissectionin clinically node negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33.PubMedCentralPubMedCrossRefGoogle Scholar
- 9.Fleissig A, Fallowfield L, Langridge CI, et al. Post-operative upper limb morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary dissection in management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95:279–93.PubMedCrossRefGoogle Scholar